Forbes J M & Co. LLP Boosts Holdings in Merck & Co., Inc. (NYSE:MRK)

Forbes J M & Co. LLP raised its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 0.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 204,773 shares of the company’s stock after acquiring an additional 1,043 shares during the quarter. Merck & Co., Inc. makes up about 1.8% of Forbes J M & Co. LLP’s holdings, making the stock its 23rd biggest holding. Forbes J M & Co. LLP’s holdings in Merck & Co., Inc. were worth $15,694,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. OLD Mission Capital LLC acquired a new stake in Merck & Co., Inc. during the third quarter worth approximately $247,000. Morgan Stanley increased its holdings in shares of Merck & Co., Inc. by 17.1% in the 2nd quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock valued at $2,044,534,000 after acquiring an additional 3,832,086 shares during the period. Keudell Morrison Wealth Management increased its holdings in shares of Merck & Co., Inc. by 2.5% in the 3rd quarter. Keudell Morrison Wealth Management now owns 18,332 shares of the company’s stock valued at $1,377,000 after acquiring an additional 453 shares during the period. New World Advisors LLC purchased a new position in Merck & Co., Inc. in the 3rd quarter valued at $414,000. Finally, AlphaCrest Capital Management LLC purchased a new position in Merck & Co., Inc. in the 3rd quarter valued at $846,000. Institutional investors own 72.88% of the company’s stock.

A number of equities analysts recently weighed in on MRK shares. Barclays lifted their price objective on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. SVB Leerink decreased their target price on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. JPMorgan Chase & Co. decreased their target price on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating on the stock in a research report on Friday, January 28th. Mizuho started coverage on shares of Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 target price on the stock. Finally, Morgan Stanley decreased their target price on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $90.69.

Shares of NYSE MRK traded down $0.01 on Thursday, reaching $92.09. 11,120,236 shares of the company traded hands, compared to its average volume of 12,248,939. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $94.56. The company has a 50 day moving average of $84.86 and a 200 day moving average of $80.85. The company has a current ratio of 1.27, a quick ratio of 1.02 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $232.88 billion, a PE ratio of 16.48, a P/E/G ratio of 1.25 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.31. The firm had revenue of $15.90 billion during the quarter, compared to the consensus estimate of $14.64 billion. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 49.57%. The company’s revenue was up 31.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.40 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.